From St. Louis to Boston, Scientists Grapple with Ethnoracial Divide in AD Biomarkers
Across several studies, black/African Americans and Hispanic or Latino people had lower amyloid positivity rates than whites. Scientists are studying why.
ALL NEWS
611 RESULTS
Sort By:
- Most Recent
- Most Commented
To Recruit for Diverse Alzheimer Trials, Go to the People
Most participants in AD research studies and trials are non-Hispanic whites. At a conference in St. Louis, scientists discussed strategies to include diverse populations.
After a Decade, Amyloid PET Scans Receive Broad Insurance Coverage
CMS has lifted restrictions that allowed beneficiaries one scan per lifetime as part of a clinical study. Approval of immunotherapies was a key factor.
Plasma Proteomics Studies Link Genetic Variants to Phenotypes
A consortium of pharma companies mined data from 50,000 people in the U.K. Biobank to turn up thousands of new gene-protein connections.
Meet the Two New Biomarker Candidates for Lewy Body Diseases
DOPA decarboxylase in blood or CSF, and damaged mitochondrial DNA in blood cells, separated cases from controls.
CSF Proteomic Panel Better Predicts Decline Than Do Classic AD Biomarkers
A curated panel of 48 proteins foretold cognitive decline. It also illuminated biological pathways involved in Alzheimer's disease.
Alzheimer’s, Primary Age-Related Tauopathy Take Separate Paths
Compared to AD, tau tangles in PART accumulated slowly, and only in the medial temporal lobe. Cognition slipped subtly, and no amyloid amassed over three years.
Direct-to-Consumer Alzheimer’s Blood Test Opens Pandora’s Box
Experts say the low specificity of Quest Diagnostics’ plasma Aβ test could lead to more false than true positives, causing distress and confusion.
Biomarkers and Efficacy: Not (Yet?) a Perfect Union
Scientists at AAIC debated discrepant results, updated a model of the biomarker-efficacy relationship, and debuted the CenTauR scale for tau PET.
Revised Again: Alzheimer's Diagnostic Criteria Get Another Makeover
The newly proposed scheme uses only amyloid and tau for diagnosis and staging. It establishes parallel tracks for fluid or imaging markers, and recognizes a clinical stage zero.
Wanted: Fluid Biomarkers for CAA, ARIA
The ability to quickly detect cerebral amyloid angiopathy and ARIA would make amyloid immunotherapy safer, but research in this area is just beginning.
Cohort LEADS Toward Better Understanding of Sporadic Early Onset AD
First data from the Longitudinal Early-Onset Alzheimer’s Disease Study hints at what might cause this type of AD and how it unfolds.
Brain Tissue From Living People with Amyloid Plaques Can Fire in a Dish
Scientists have established acute slice recordings from cerebral cortex biopsies. They find circuitry and basic function to be preserved. They also find changes in the presence of Alzheimer's pathology.
A Day's Work: Cortex Biopsy Comes Out. Shunt Goes In. Patient Goes Home.
Every week in a Finnish operating room, bits of human cortex get lifted from brains and straight into electrophysiology rigs. Other tissues go to diagnostic and research labs, or biobanks, for ADRD research. Read how it happens.
Fresh Brain Every Friday: Biopsies Transform Alzheimer's Science
In the Finnish city of Kuopio, surgeons and scientists have built a unique protocol. It improves life for people with hydrocephalus—and it banks cortical tissue rife with preclinical pathology and gene variants for Alzheimer's research.
Current Filters
- Biomarkers x